- Home
- PROK
PROK
ProKidney Corp.
as 01-17-2025 4:00pm EST
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.
| Founded: | 2015 | Country: | United States |
| Employees: | 163 | City: | WINSTON-SALEM |
| Market Cap: | 212.4M | IPO Year: | N/A |
| Target Price: | $4.50 | AVG Volume (30 days): | 566.3K |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.56 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.18 - $4.44 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest ProKidney Corp. News
PROK Breaking Stock News: Dive into PROK Ticker-Specific Updates for Smart Investing
GlobeNewswire
12 days ago
ProKidney to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Simply Wall St.
14 days ago
One ProKidney Insider Raised Their Stake In The Previous Year
GlobeNewswire
2 months ago
ProKidney to Participate in Two Upcoming Conferences: Evercore HealthCONx Conference and the Citi Global Healthcare Conference
Simply Wall St.
2 months ago
US Penny Stocks To Watch: 3 Picks With Market Caps Under $500M
MT Newswires
2 months ago
ProKidney Q3 Net Loss Narrows; Cash on Hand to Fund Operations Until 2027
GlobeNewswire
2 months ago
ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting
GlobeNewswire
2 months ago
ProKidney to Participate in the Guggenheim Inaugural Healthcare Innovation Conference and the Jefferies London Healthcare Conference
GuruFocus.com
3 months ago
Suvretta Capital Management's Strategic Acquisition in ProKidney Corp
Compare PROK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PROK ProKidney Corp. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.